Text and Data Mining valid from 2019-03-29
Received: 19 July 2018
Accepted: 13 February 2019
First Online: 29 March 2019
: M.M., employed by MLL Munich Leukemia Laboratory; R.C.L., research funding from MedImmune and Jazz, and consulting fees from Takeda; B.L.E., research funding from Celgene and Deerfield, and consulting fees from GRAIL; T.H., equity ownership of MLL Munich Leukemia Laboratory; C.G.M., research funding from Loxo Oncology for TRK inhibitors in acute lymphoblastic leukemia, and Abbvie and Pfizer for studies unrelated to those described herein. C.G.M. has received honoraria and travel support from Pfizer and Amgen.